Introduction
Oral antiviral medications are important tools for preventing severe COVID-19 outcomes. However, their uptake remains low for reasons that are not entirely understood. Our study aimed to assess the association between perceived risk for severe COVID-19 outcomes and oral antiviral use among those who were eligible for treatment based on Centers for Disease Control and Prevention (CDC) guidelines.
Methods
We surveyed 4034 non-institutionalized US adults in April 2023, and report findings from 934 antiviral-eligible participants with at least one confirmed SARS-CoV-2 infection since December 1, 2021 and no current long COVID symptoms. Survey weights were used to yield nationally representative estimates. The primary exposure of interest was whether participants perceived themselves to be “at high risk for severe COVID-19.” The primary outcome was use of a COVID-19 oral antiviral within 5 days of suspected SARS-CoV-2 infection.
Results
Only 18.5% of antiviral-eligible adults considered themselves to be at high risk for severe COVID-19 and 16.8% and 15.9% took oral antivirals at any time or within 5 days of SARS-CoV-2 infection, respectively. In contrast, 79.8% were aware of antiviral treatments for COVID-19. Perceived high-risk status was associated with being more likely to be aware (adjusted prevalence ratio [aPR]: 1.11 [95% confidence interval (CI) 1.03–1.20]), to be prescribed (aPR 1.47 [95% CI 1.08–2.01]), and to take oral antivirals at any time (aPR 1.61 [95% CI 1.16–2.24]) or within 5 days of infection (aPR 1.72 [95% CI 1.23–2.40]).
Conclusions
Despite widespread awareness of the availability of COVID-19 oral antivirals, more than 80% of eligible US adults did not receive them. Our findings suggest that differences between perceived and actual risk for severe COVID-19 (based on current CDC guidelines) may partially explain this low uptake.
Supplementary Information
The online version contains supplementary material available at 10.1007/s40121-024-01003-3.
